For the first time in over a century, children with diabetes now have a choice that doesn't require a needle before meals. The FDA has approved Afrezza, an inhaled insulin powder made by MannKind, for children and adolescents aged 6 and older living with type 1 or type 2 diabetes—a decision that reshapes how young patients and their families manage daily insulin therapy.
The approval matters because insulin management has long defined childhood diabetes care: multiple daily injections, careful meal planning hours in advance, and the constant logistical challenge of carrying needles and supplies everywhere a child goes. Afrezza changes that equation. The medication delivers insulin through the lungs using MannKind's Technosphere technology, which enables rapid absorption that closely mimics the body's natural insulin response at mealtime. Most importantly, children can now take it at the moment they eat—no premeal planning required, no surprises about snacks derailing the day's schedule.
The FDA's decision rests on solid clinical ground. The approval was based on results from the phase 3 INHALE-1 study of pediatric patients, combined with more than 20 years of safety and efficacy data from thousands of patients across multiple clinical trials. Afrezza was already approved for adults, but extending it to children aged 6 and up significantly broadens access to this alternative therapy. The Technosphere platform itself has been rigorously tested across two decades of use, giving families confidence in both its effectiveness and safety profile.
Michael Castagna, MannKind's chief executive officer, captured the human significance in his statement about the approval: "For more than a century, insulin therapy for children living with diabetes has largely meant multiple daily injections. Afrezza allows dosing at the moment of eating, without the need for premeal planning, making it a practical option for unplanned meals and snacks on the go." That simplicity—the ability to respond naturally to a child's actual eating patterns rather than forcing eating patterns around insulin schedules—represents a genuine shift in quality of life.
For children juggling school, sports, sleepovers, and the simple unpredictability of being young, this matters deeply. A child no longer needs to inject insulin before every meal or snack, calculate timing in advance, or explain their medical routine to friends and teachers. The flexibility Afrezza provides aligns insulin therapy with how children actually live, rather than asking children to restructure their lives around insulin.
The approval also reflects MannKind's commitment to expanding treatment options in diabetes care. By bringing an already-proven adult therapy to the pediatric population, the company has opened a door that patients and families have been waiting for. For children diagnosed with diabetes, this approval means more autonomy, less daily burden, and a therapy that works with their lives rather than against them. It's a reminder that innovation in medicine often comes not from inventing something entirely new, but from making existing solutions accessible to those who need them most.